R-engineered NK cells; A Promising TherapeuticOption for Multiple Myeloma

Multiple myeloma (MM) is a hematological malignancy thataffects the plasma cells. Despite novel therapeutic advantagesin recent years, the majority of patients experience relapse andhave a poor prognosis, indicating the need for additional treatmentstrategies. In recent years, chimeric antigen receptor Tcell(CAR-T cell) therapy has brought hope to patients with refractoryand relapsed MM. Chimeric antigen receptors (CARs)are a novel aspect of synthetic biology and represent a paradigmchange in personalized medicine because of their ability to employand reroute immune cells to attack cancer cells. However,the toxicity and significant limitations of CAR-T cell immunotherapyhave prompted research on other immune cells aspotential candidates for CAR engineering. Therefore, NK cellsare being explored as an alternative platform for CAR engineeringas a significant player in the next generation of cellulartherapies targeting cancer. CAR-NK cell immunotherapy is anovel anti-MM therapeutic method that has the potential to improveMM survival in the future. CAR-NK cells can be utilizedas a universal cell-based therapy without the need for humanleukocyte antigen (HLA) matching or prior contact with tumorassociatedantigens (TAAs), which allows the production of NKcell banks instead of individual CAR NK cells. Therefore, CARNK cell therapies may lead to revolutionary advances in tumorimmunotherapy. This review discusses adoptive cell therapies,including CAR T-cell and CAR NK cell therapies, for patientswith MM.

کلیدواژه ها:

Adoptive cell therapy ، Chimeric Antigen Receptors ، CAR-T cells ، CAR NK cells ، Multiple Myeloma (MM).